Company intelligence / Profile preview
Caelus Health
- Ownership
- Private
- Development stage
- Other
Overview
Caelus has demonstrated early clinical proof-of-concept that its lead live biotherapeutic product based on Eubacterium hallii can improve glycemic control in subjects at risk of type II diabetes. Additional programs are advancing through preclinical and early clinical development targeting metabolic and immune-related disorders. The company’s approach is supported by strong academic collaborations and a strategic partnership with Nestlé Health Science for global development rights to key pipeline assets.
- Therapeutic areas
- ImmunologyMetabolic DisordersEndocrinologyOncology
- Modalities
- Live biotherapeutic products (LBPs)Microbiota-based therapeuticsSmall moleculesFecal microbiota transplantation (FMT)
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Caelus Health.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Caelus Health.